PHARMACODYNAMIC PROFILE OF VERAPAMIL IN RELATION TO ABSOLUTE BIOAVAILABILITY - INVESTIGATIONS WITH A CONVENTIONAL AND A CONTROLLED-RELEASE FORMULATION

被引:21
作者
HARDER, S [1 ]
THURMANN, P [1 ]
SIEWERT, M [1 ]
BLUME, H [1 ]
HUBER, T [1 ]
RIETBROCK, N [1 ]
机构
[1] ZENT LAB DEUTSCH APOTHEKER EV,ESCHBORN TAUNUS,GERMANY
关键词
D O I
10.1097/00005344-199102000-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The absolute bioavailability F and response (prolongation of the PR interval) of verapamil after single doses of the same oral formulation administered on two different days were investigated in 16 male subjects with an 80 mg fast dissolving and a 240 mg controlled-release preparation and compared with a bolus injection of 5 mg of verapamil. The absolute bioavailability was 23% in both investigations for the 80 mg preparation and 32% in both investigations for the 240 mg dosage form. The individual values obtained for t(max), c(max), F, and AUC0-infinity showed a wide intersubject variability; therefore, no significant differnces could be observed between the two trials for each dosage, but significant differences existed between the investigations of the two preparations. After intravenous administration, concentration-effect curves were about twofold left shifted when compared with the 80 mg tablet and about threefold left shifted when compared with the 240 mg tablet. Estimation of the drug input rate showed significantly (p < 0.05) smaller values when the controlled-release tablet was given (80 mg tablet: 95.1 and 107.7 mg/h; 240 mg tablet: 55.8 and 46.3 mg/h). Thus, the effect and bioavailability of verapamil show sufficient intersubject reproducibility if the same formulation is given. The differences between the responses and the bioavailability after administration of different preparations may be related as well to the drug absorption rate and the stereoselective first pass of verapamil as to saturation of first-pass metabolism.
引用
收藏
页码:207 / 212
页数:6
相关论文
共 24 条
[1]  
ABERNETHY DR, 1988, J CARDIOVASC PHARM, V11, P209
[2]  
ASTHANA OP, 1984, ARZNEIMITTELFORSCH, V34-1, P498
[3]  
BARBIERI E, 1985, INT J CLIN PHARM RES, V2, P99
[4]  
BUHLER V, 1984, ARCH PHARM S, V325, pA344
[5]   THE USE OF KINETIC-DYNAMIC INTERACTIONS IN THE EVALUATION OF DRUGS [J].
CAMPBELL, DB .
PSYCHOPHARMACOLOGY, 1990, 100 (04) :433-450
[6]  
CASHMAN JR, 1989, MOL PHARMACOL, V36, P497
[7]   DETERMINATION OF THE ENANTIOMERS OF VERAPAMIL AND NORVERAPAMIL IN SERUM USING COUPLED ACHIRAL CHIRAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
CHU, YQ ;
WAINER, IW .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 497 :191-200
[8]  
DERENDORF H, 1987, PHARMAKOKINETIK
[9]  
DONELLY R, 1988, J CARDIOVASC PHAR S6, V12, pS109
[10]  
DUNN JM, 1984, CURR THER RES, V38, P572